Families who have lost loved ones to the opioid epidemic should be pleased that five chairmen of pharmaceutical distribution companies have been called before Congress to account for their actions. These executives could be required to fund the recovery of millions of Americans, depending on the findings of Congress.
In the last few years, the massive role pharmaceutical companies played in increasing the U.S. rate of addiction has been revealed. Is it time to hold these huge corporations responsible for their misdeeds?
For a mother of a person struggling with opioid addiction, there’s only one motivation: Saving her child’s life. For a number of pharmaceutical companies, there's an entirely different motivation: Raking in billions in profits from drugs that are more in demand because of the opioid epidemic.
Finally, there are definite signs that major pharmaceutical companies are being assigned proper accountability for contributing to America’s terrible opioid abuse epidemic.
In New York City, Queens pharmaceutical distributor and its parent company. Kinray, LLC will be paying a $10 million penalty and parent company Cardinal will be yielding an additional $34 million to the DEA. Their offenses? Failing to report drugstores making excessive orders of addictive substances.